Drive Study Design Decisions with Bioinformatics
Therapeutic discovery goes hand in hand with risk; not just the risk of failure, but the risk of extending the cost and lead time to market by proceeding with limited information. The greater the understanding of a molecule you can develop during the early stages, the greater the opportunity to remove redundancy from your route to market with an effective and safe treatment.
eGuide for Off-Target Screening via the Retrogenix Platform
Download the eguide for all the information you need on how the Retrogenix platform can be leveraged to screen for specificity in vitro against a physiologically relevant human protein library from early-phase discovery onwards, to aid candidate selection, downstream study design, and IND approval.
Download now
Bioinformatic analysis provided by our partners Fios Genomics can offer the additional information and context around Retrogenix® human protein library binding events that you need; to add efficacy and efficiency to your downstream workflows. By integrating bioinformatics into the Retrogenix® screening workflow, we are typically able to execute the analysis with a much shorter lead time than if analysis was undertaken as a standalone study.
Bioinformatic analysis reports are fully interactive and can:
- Help focus future studies on specific tissue types / anatomical systems
- Highlight potential off-target effects (e.g., unexpected localized off-target expression)
- Highlight associated disease traits of primary and off-targets
- Indicate if a molecule exists that already targets the protein and / or off-target, and what clinical phase the molecule progressed to
- Identify the frequency of variation in a target gene which could suggest non-uniform response to a potential molecule as well as the ability to stratify patient demographics
Reports can be tailored to include additional information. Talk to our team to discuss your options.
Workflow From Study Material Delivery to Report Generation
Click each workflow stage to learn more.
Frequently Asked Questions (FAQs) About Bioinformatic Analysis
-
Does bioinformatic screening add significant lead time to a Retrogenix® screen?
Bioinformatic analysis is typically rapid and does not add significant lead time to a Retrogenix® screen. Screening data is delivered upon conclusion of the Retrogenix® study, with access to bioinformatics data following as soon as it becomes ready, typically within a month.
-
Can I add additional elements to my bioinformatics report, which are not usually included as standard?
Bioinformatic analysis is customizable upon request. Please contact us to discuss your requirements and options.
-
In what format is the bioinformatics report delivered?
Your bioinformatics data is available as a fully interactive report via portal access. Your data is also fully exportable to PDF.
-
If I’ve screened a test article via the Retrogenix® Platform previously, can I have bioinformatic analysis performed retrospectively?
Yes, if you have commissioned a study using the Retrogenix® Platform within the last two years, we can perform bioinformatic analysis retrospectively. Please get in touch to discuss your options.
-
Is it possible to opt out of bioinformatic analysis?
Retrogenix® screens are highly tailorable. Our team of specialists are happy to work with you to customize your study design. Get in touch with us to discuss your study design options.
-
What if my molecule shows no unexpected or off-target binding?
Where a molecule is exquisitely specific to its primary target, we will work with you to determine whether additional bioinformatic analysis is required.